(2023, January 12)
An important distinction from the FDA criteria is that the WHO guideline does not extend its recommendation to adults with a BMI between 27 and 30 who have obesity-related conditions
Semaglutide shows promise as a potential alcohol use disorder medication Intramural scientists at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA), and collaborators from The Scripps Research Institute, found that semaglutide reduces alcohol consumption and binge-like drinking in a rodent model of alcohol misuse
Diabetologia 65(12):19251966 Berra C, Manfrini R, Mirani M, Bucciarelli L, Zakaria AS, Piccini S et al (2023) AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus
Performance improvements stem from enhanced recovery capacity rather than direct performance enhancement
And Jim, just recently, a couple days ago, and we're going to need to do a whole episode on it, there was a, I think, a Cleveland Clinic analysis that showed decreased progression of metastatic cancer and, you know, several different kinds of cancers, meaning decreased metastatic disease, which is huge